NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
12/08/2026
Voltar para busca
Dado oficial do USPTO
RAAS TRIPLE-A
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
RAAS TRIPLE-A
ST13
US500000079256903Classe
1, 5, 9, 42, 44
Pedido
79256903
Registro
5993170
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
12/08/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 9, 42, 44
Data de depósito
19/12/2018
Data de registro
25/02/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
12/08/2026
Última transação
12/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
707
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
16
Localização do titular
Wien, AT
Examinador
STEIN, JAMES W
Localização atual
Historical data usage
Titulares e representantes
Titulares
ATTOQUANT DIAGNOSTICS GMBH
ATTOQUANT DIAGNOSTICS GMBH
Representantes
Michael J. Leonard Fox Rothschild LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 9Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalbiochemical and biotechnological productschemicalbiochemical and biotechnological agents used for non-medical purposesagents for quantifying and analyzing peptidesenzymeshormones and metabolites involved in the renin-angiotensin-aldosterone system; chemical preparationschemical preparations for quantifying and analyzing peptidesenzymeshormones and metabolites involved in the renin-angiotensin-aldosterone system; biochemical agentsbiochemical agents for quantifying and analyzing peptidesenzymeshormones and metabolites involved in the renin-angiotensin-aldosterone system; buffersbuffers for quantifying and analyzing peptidesenzymeshormones and metabolites involved in the renin-angiotensin-aldosterone system
Classe 5
Diagnostic agents for pharmaceutical purposes containing chemical preparationsbiochemical agentsbuffersdiagnostic reagentsalso in the form of kitsfor medical purposes in the field of treating diseases related to the renin-angiotensin-aldosterone systemincluding cardiovascular disordersin particular hypertension and primary aldosteronism
Classe 9
Downloadable computer softwareapplication softwaremobile application softwaresoftware development tools in the nature of computer softwaredatabase software in the nature of computer software for use in database managementall aforementioned goods downloadable and related to the medical fieldfor researching diagnosingpreventingcombatingtreating and monitoring the treatment of diseases related to the renin-angiotensin-aldosterone systemincluding cardiovascular disordersin particular hypertension and primary aldosteronism
Classe 42
Medical and scientific research and analysis services in the nature of quality measurement and analysis for medical practicessoftware design and development concerning quantifying and analyzing peptidesenzymeshormones and metabolites involved in the renin-angiotensin-aldosterone system in the field of researchingdiagnosingpreventingcombatingtreatingmonitoring the treatment of diseases related to the renin-angiotensin-aldosterone systemincluding cardiovascular disordersin particular hypertension and primary aldosteronism
Classe 44
Medical servicesmedical caremedical testing in the nature of medical diagnostic testing ; providing information in the field of medical informationin the fields of diagnosingpreventingcombatingtreating and monitoring the treatment of diseases related to the renin-angiotensin-aldosterone systemincluding cardiovascular disordersin particular hypertension and primary aldosteronism
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
12/08/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
15/06/2026
ES71
TEAS SECTION 71 RECEIVED
24/02/2026
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
25/02/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/11/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
26/11/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
17/07/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
25/06/2020
FIMP
FINAL DISPOSITION PROCESSED
25/06/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
25/05/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
25/02/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/12/2019
PUBO
PUBLISHED FOR OPPOSITION
10/12/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/11/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/11/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
03/11/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/11/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
03/11/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/11/2019
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
17/09/2019
GNFR
FINAL REFUSAL E-MAILED
17/09/2019
CNFR
FINAL REFUSAL WRITTEN
17/09/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/08/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/08/2019
ALIE
ASSIGNED TO LIE
14/08/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/08/2019
RFNT
REFUSAL PROCESSED BY IB
08/06/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
22/05/2019
RFRR
REFUSAL PROCESSED BY MPU
22/05/2019
MAFR
APPLICATION FILING RECEIPT MAILED
30/04/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
26/04/2019
CNRT
NON-FINAL ACTION WRITTEN
25/04/2019
DOCK
ASSIGNED TO EXAMINER
24/04/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
24/04/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
18/04/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace RAAS TRIPLE-A ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.